香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 內幕消息 訴訟公告 本公告乃億達中國控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）根據 香港聯合交易所有限公司證券上市規則第13.09條及香港法例第571章證券及期貨 條例第XIVA部項下之內幕消息條文（定義見上市規則）而作出。 茲提述本公司日期為二零二五年十月十七日之公告（「該公告」）。除另有界定外， 本公告所用詞彙與該公告所界定者具有相同涵義。 訴訟 誠如該公告所披露，本公司附屬公司榮泰公司、鄭州億達未能清償北方信託貸款 本金及對應利息。日前，本公司附屬公司收到天津市第二中級人民法院送達的 北方信託（「原告」）訴榮泰公司（「被告一、借款人、抵押人」）、鄭州億達（「被告 二、共同還款人、抵押人」）、大連軟件園榮源開發有限公司（「被告三、抵押人」） 及大連嘉道科技發展有限公司（「被告四、抵押人」）的《民事起訴狀》。原告訴請判 令：(i)被告一及被告二清償借款本金約人民幣4.82億元及對應利息、罰 ...

【财华社讯】12月18日午盘，截至发稿，港股涨幅榜前十名分别为华美乐乐(08429.HK)涨幅45.28%、高 科桥(09963.HK)涨幅44.44%、亿达中国(03639.HK)涨幅36.36%、森美控股(00756.HK)涨幅31.43%、植华 集团(01842.HK)涨幅29.41%、协同通信(01613.HK)涨幅13.92%、奥传思维控股(08091.HK)涨幅12.50%、 富通科技(00465.HK)涨幅12.28%、中科生物(01237.HK)涨幅11.69%、高原之宝(08402.HK)涨幅11.03%。 序号代码名称涨跌额(%)最新价108429.HK华美乐乐+45.280.077209963.HK高科桥+44.440.780303639.HK 亿达中国+36.360.060400756.HK森美控股+31.430.460501842.HK植华集团+29.410.066601613.HK协同通 信+13.920.180708091.HK奥传思维控股+12.500.036800465.HK富通科技+12.280.640901237.HK中科生物 +11.690.8601008402.HK高 ...

Market Overview - The Hong Kong stock market experienced fluctuations and adjustments, with the Hang Seng Index down 0.92% to 25,737.85 points, the Hang Seng Tech Index down 1.79% to 5,537.11 points, the National Enterprises Index down 1.2% to 8,970.29 points, and the Red Chip Index down 0.3% to 4,137.97 points due to the significant drop in US stocks last Friday [1] - Major technology stocks saw declines, with Alibaba down 2.73%, Tencent Holdings down 1.54%, JD Group down 1.12%, Xiaomi down 2.28%, NetEase down 0.18%, Meituan down 1.07%, Kuaishou down 3.85%, and Bilibili down 1.12% [1] - Insurance stocks performed well, with China Ping An reaching a four-year high, while the biopharmaceutical sector weakened, with Baijiazhensheng down over 6% [1] - Semiconductor stocks faced significant declines, with Huahong Semiconductor down over 6% [1] Company News - China Merchants Energy (01138.HK) signed shipbuilding contracts with Dalian China Merchants Heavy Industry, Yangzhou China Merchants Heavy Industry, and Guangdong China Merchants Heavy Industry for the construction of one ethylene ship and eighteen oil tankers, with a total cost of RMB 7.882 billion [2] - ZhongAn Online (06060.HK) reported a cumulative original insurance premium income of approximately RMB 32.904 billion for the first eleven months [3] - R&F Properties (02777.HK) achieved total sales revenue of approximately RMB 12.7 billion in the first eleven months, representing a year-on-year increase of 24.63% [4] - Yida China (03639.HK) reported a contract sales amount of approximately RMB 681 million for the first eleven months, a year-on-year decrease of 23.22% [5] - Kason International (00496.HK) signed a steel structure procurement contract with suppliers, involving an investment of RMB 43.5366 million [5] Clinical and Regulatory Updates - Boke Vision Cloud-B (02592.HK) successfully held a meeting after the second phase of clinical trials for CBT-004 [6] - Fuhong Hanlin (02696.HK) received acceptance from the National Medical Products Administration for the listing registration application of Hanshuo® in combination with chemotherapy for neoadjuvant/adjuvant treatment of gastric cancer, which has been included in priority review [6] - Shijiazhuang Pharmaceutical Group (01093.HK) received approval for a new indication for Donyi® (liposomal irinotecan injection) for first-line treatment in patients with metastatic pancreatic cancer [6] - Hengrui Medicine (01276) received a clinical trial approval notice for HRS-1780 tablets [8] Investment Insights - Guosen Securities indicated that the short-term adjustment in the Hong Kong stock market opens up space for a market rise in 2026, with net inflows from southbound funds exceeding RMB 110 billion in November [13] - Dongwu Securities highlighted that the main focus for Hong Kong stocks is on technology and cyclical sectors, while also paying attention to innovative drugs, suggesting a barbell allocation strategy due to potential macro and political risks [13] - CITIC Securities projected that the Hong Kong stock market will benefit from internal "14th Five-Year Plan" catalysts and external fiscal and monetary easing from major economies, expecting a sustainable upward trend in revenue and profit [13] - Dongwu Securities also forecasted a continued recovery in the Hong Kong stock market in 2026, citing expected interest rate cuts by the Federal Reserve and a temporary easing of Sino-US relations [14]

Market Overview - The Hong Kong stock market opened lower on December 15, with the Hang Seng Index down 1% at 25,718.14 points, the Hang Seng Tech Index down 1.34% at 5,562.67 points, and the State-Owned Enterprises Index down 1.09% at 8,980.13 points [1] - Major tech stocks declined, including Alibaba down 2.14%, Tencent down 1.62%, and JD.com down 0.61% [1] - The innovative drug sector saw several stocks open lower, with Genscript Biotech down 5.92% and Zai Lab down 3.48% [1] - Chinese brokerage stocks collectively fell, with Everbright Securities dropping over 1% [1] - The automotive sector also experienced declines, with Li Auto down over 2% and XPeng down nearly 2% [1] - However, three-child policy concept stocks and photovoltaic stocks mostly rose, with star stock Jinxin Fertility rising about 3% [1] Company News - China Merchants Energy (01138.HK) signed shipbuilding contracts for one ethylene ship and eighteen oil tankers, totaling RMB 7.882 billion [2] - ZhongAn Online (06060.HK) reported cumulative original insurance premium income of approximately RMB 32.904 billion for the first eleven months [3] - R&F Properties (02777.HK) achieved total sales revenue of approximately RMB 12.7 billion in the first eleven months, a year-on-year increase of 24.63% [4] - Yida China (03639.HK) reported contract sales amounting to approximately RMB 681 million in the first eleven months, a year-on-year decrease of 23.22% [5] - Bole Technology (02592.HK) successfully held a meeting after the second phase of clinical trials for CBT-004 [6] - Junshi Biosciences (02696.HK) received acceptance for its marketing application for Hansizhuang® in combination with chemotherapy for gastric cancer [6] - CSPC Pharmaceutical Group (01093.HK) received approval for a new indication for its drug, Donyin® (liposomal irinotecan injection), for first-line treatment in metastatic pancreatic cancer patients [6] - Biyuan (00926.HK) increased its investment in ERX to maintain a 3% stake to support innovative research and development of non-GLP-1 weight loss therapies [7] - Hengrui Medicine (01276) received approval for clinical trials for HRS-1780 tablets [8] - AVIC Industry (02357.HK) plans to acquire a 59.1816% partnership interest in Hangtou Yuhua for a consideration of RMB 202 million [9] - China Environmental Resources (01130.HK) intends to acquire 90% equity in Sichuan Yuanlai Shun Recycling Resources Co., Ltd. for RMB 9 million [10] - AVIC Industry (02357.HK) proposed to implement full circulation of H-shares [11] - Yabo Technology Holdings (08279.HK) signed a framework agreement with Alipay (Hangzhou) [12] Institutional Insights - Guosen Securities indicated that the short-term adjustment in the Hong Kong stock market opens up space for a market rise in 2026, with net inflows from southbound funds exceeding RMB 110 billion in November [13] - CITIC Securities noted strong performance in gold and silver, while other risk assets were weak, predicting a segmented market for precious metals in 2025 [13] - CITIC Securities also emphasized the importance of resource self-sufficiency in the lithium industry, highlighting the need for low-cost quality resources to navigate market cycles [14]

Company News - China COSCO Shipping Energy Transportation Co., Ltd. (中远海能) has signed shipbuilding contracts with Dalian COSCO Shipping Heavy Industry, Yangzhou COSCO Shipping Heavy Industry, and Guangdong COSCO Shipping Heavy Industry for the construction of one ethylene ship and eighteen oil tankers, with a total cost of RMB 7.882 billion [1] - ZhongAn Online P&C Insurance Co., Ltd. (众安在线) reported a total original insurance premium income of approximately RMB 32.904 billion for the first eleven months [2] - R&F Properties Co., Ltd. (富力地产) achieved total sales revenue of approximately RMB 12.7 billion in the first eleven months, representing a year-on-year increase of 24.63% [3] - Yida China Holdings Limited (亿达中国) reported a contracted sales amount of approximately RMB 681 million for the first eleven months, a year-on-year decrease of 23.22% [4] - Karsen International Holdings Limited (卡森国际) has entered into a steel structure procurement contract with suppliers, involving an investment of RMB 43.5366 million [4] Clinical and Regulatory Updates - Bolex Cloud-B (拨康视云-B) successfully held a meeting after the second phase of clinical trials for CBT-004 [5] - Innovent Biologics, Inc. (复宏汉霖) has had its application for the marketing registration of Hansizhuang® combined chemotherapy for gastric cancer accepted by the National Medical Products Administration, and it has been included in the priority review [5] - CSPC Pharmaceutical Group Limited (石药集团) received approval for a new indication for Donyi® (Irinotecan Liposome Injection) for first-line treatment in patients with metastatic pancreatic cancer [5] - Heng Rui Medicine (恒瑞医药) received a clinical trial approval notice for HRS-1780 tablets [7] Investment and Acquisition Activities - AVIC Aviation Industry Corporation (中航科工) plans to acquire a 59.1816% partnership interest in Hangtou Yuhua for a consideration of RMB 202 million [8] - China Environment Resources Holdings Limited (中国环境资源) intends to acquire 90% equity in Sichuan Yuanlai Shun Recycling Resources Co., Ltd. for RMB 9 million [9] - AVIC Aviation Industry Corporation (中航科工) has proposed to implement full circulation of H-shares [10] - Yabo Technology Holdings Limited (亚博科技控股) has entered into a framework agreement with Alipay (Hangzhou) [11] Financing and Buyback Activities - Yum China Holdings, Inc. (百胜中国) has entered into a share buyback agreement with a total repurchase amount of approximately USD 460 million, including about HKD 880 million under the Hong Kong plan, as part of a plan to return USD 1.5 billion to shareholders through dividends and share buybacks by 2026 [12] - Tencent Holdings Limited (腾讯控股) repurchased approximately 1.044 million shares for about HKD 636 million, with repurchase prices ranging from HKD 601.5 to HKD 616 [13] - Xuanwu Cloud (玄武云) repurchased 6,000 shares for a total of HKD 6,467.79, with prices between HKD 1.05 and HKD 1.07 [14] - China COSCO Shipping Holdings Co., Ltd. (中远海控) repurchased approximately 4.461 million shares for about HKD 60.8605 million, with prices ranging from HKD 13.38 to HKD 13.82 [15] - Geely Automobile Holdings Limited (吉利汽车) repurchased approximately 1.362 million shares for about HKD 23.9241 million, with prices between HKD 17.29 and HKD 17.82 [16] - China Anshun Energy (中国安储能源) plans to issue a total of 524 million shares at a discount of approximately 19.12%, aiming to raise about HKD 288.2 million [16]

亿达中国(03639)发布公告，于2025年11月，本集团的合约销售金额约为人民币0.30亿元及本集团的权益 合约销售金额约为人民币0.30亿元。同期，本集团的销售面积为2189平方米及权益销售面积为2189平方 米，本集团的销售均价约为每平方米人民币1.36万元及权益销售均价约为每平方米人民币1.36万元。 截至2025年11月30日止11个月，本集团的合约销售金额约为人民币6.81亿元及本集团的权益合约销售金 额约为人民币6.62亿元，分别同比减少23.22%及22.84%。同期，本集团的销售面积为5.47平方米及权益 销售面积为5.17万平方米，本集团的销售均价约为每平方米人民币1.25万元及权益销售均价约为每平方 米人民币1.28万元。 ...

智通财经APP讯，亿达中国(03639)发布公告，于2025年11月，本集团的合约销售金额约为人民币0.30亿 元及本集团的权益合约销售金额约为人民币0.30亿元。同期，本集团的销售面积为2189平方米及权益销 售面积为2189平方米，本集团的销售均价约为每平方米人民币1.36万元及权益销售均价约为每平方米人 民币1.36万元。 截至2025年11月30日止11个月，本集团的合约销售金额约为人民币6.81亿元及本集团的权益合约销售金 额约为人民币6.62亿元，分别同比减少23.22%及22.84%。同期，本集团的销售面积为5.47平方米及权益 销售面积为5.17万平方米，本集团的销售均价约为每平方米人民币1.25万元及权益销售均价约为每平方 米人民币1.28万元。 ...

格隆汇12月12日丨亿达中国(03639.HK)公告，于2025年11月，集团的合约销售金额约为人民币0.30亿元 及集团的权益合约销售金额约为人民币0.30亿元。同期，集团的销售面积为2,189平方米及权益销售面积 为2,189平方米，集团的销售均价约为每平方米人民币13,563元及权益销售均价约为每平方米人民币 13,563元。 截至2025年11月30日止十一个月，集团的合约销售金额约为人民币6.81亿元及集团的权益合约销售金额 约为人民币6.62亿元。同期，集团的销售面积为54,647平方米及权益销售面积为51,653平方米，集团的 销售均价约为每平方米人民币12,467元及权益销售均价约为每平方米人民币12,807元。 ...

二零二五年十一月未經審核營運數據 億達中國控股有限公司（「本公司」）董事會（「董事會」）宣佈本公司及附屬公司 （「本集團」）就二零二五年十一月的若干未經審核營運數據統計如下： 上述銷售數據未經審核，乃根據本集團初步內部資料編製，該等銷售數據與本公 司按年度或半年度刊發的經審核或未經審核綜合財務報表中披露的數據可能存在 差異。因此，上述數據僅供投資者參考。投資者買賣本公司證券時務須謹慎行 事，並避免不恰當地依賴該等資料。如有任何疑問，投資者應尋求專業人士或財 務顧問的專業意見。 億達中國控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：3639） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 YIDA CHINA HOLDINGS LIMITED 1 • 於二零二五年十一月，本集團的合約銷售金額約為人民幣0.30億元及本集團 的權益合約銷售金額約為人民幣0.30億元。同期，本集團的銷售面積為2,189 平方米及權益銷售面積為2,189平方米， ...

Core Insights - As of December 10, 30 stocks reached their 52-week highs, with Design Metropolis (01545), Platinum Holdings (00459), and China Boton (03318) leading the increase rates at 40.82%, 35.48%, and 30.23% respectively [1][2] 52-Week Highs - Design Metropolis (01545) closed at 0.124, with a peak of 0.138, achieving a high rate of 40.82% [1] - Platinum Holdings (00459) closed at 0.121, with a peak of 0.126, achieving a high rate of 35.48% [1] - China Boton (03318) closed at 2.090, with a peak of 2.800, achieving a high rate of 30.23% [1] - Other notable stocks include: - China New Holdings (08125) at 25.00% [1] - Qiaoyang International Holdings (08070) at 14.46% [1] 52-Week Lows - The stock with the largest decline was Jingye Mingbang Group (02231), which fell to 0.099, a decrease of 26.40% [2] - Other significant declines included: - Zhonggang Petroleum (00632) at -16.40% [2] - Guofu Hydrogen Energy (02582) at -13.31% [2] - Additional stocks with notable declines: - Haotian International Construction Investment (01341) at -11.11% [2] - Jiaming Group Holdings (01271) at -10.00% [2]